Announcement of The Consolidated Financial Report for The 1st Quarter of 2025
2025.5.14
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2025/05/14 | Time of announcement | 18:17:44 |
| Subject | Announcement of The Consolidated Financial Report for The 1st Quarter of 2025 | ||||
| Date of events | 2025/05/14 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2025/05/14 2.Date of the audit committee approved:2025/05/14 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2025/01/01~2025/03/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):1,458,850 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):883,531 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):412,145 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):515,596 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):408,082 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):391,096 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):1.57 11.Total assets end of the period (thousand NTD):10,972,636 12.Total liabilities end of the period (thousand NTD):4,084,616 13.Equity attributable to owners of parent end of the period (thousand NTD):6,118,191 14.Any other matters that need to be specified:None |
||||